Aventis/Dermik’s Facial Repair Device Gets Compassionate Panel Nod
This article was originally published in The Gray Sheet
Executive Summary
FDA should actively restrict access to Aventis/Dermik Labs' Sculptra injectable facial restoration agent to patients with HIV-related lipoatrophy, according to FDA's General & Plastic Surgery Devices Panel
You may also be interested in...
Aventis HIV Dermal Filler Approval Precedes Broader Cosmetic Trial
Dermik Laboratories expects to launch a clinical trial by year-end to assess its Sculptra injectable poly-L-lactic acid as a cosmetic filler for the general population
Aventis HIV Dermal Filler Approval Precedes Broader Cosmetic Trial
Dermik Laboratories expects to launch a clinical trial by year-end to assess its Sculptra injectable poly-L-lactic acid as a cosmetic filler for the general population
Aventis Gains Expedited Review, March Panel For HIV-Indicated Dermal Filler
Expedited review of Aventis/Dermik Laboratories' Sculptra dermal filler to treat facial lipoatrophy in HIV-positive patients will precede a planned U.S. wrinkle indication, the firm says